levodopa has been researched along with Paranoia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, K | 1 |
| Helscher, RJ; Pinter, MM | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Bailbé, M; Dumas, P; Gil, R; Karolewicz, S; Neau, JP | 1 |
| Moore, DP | 1 |
| Angrist, B; Gershon, S | 1 |
| Fenton, ML; Harnett, DS; Rosenthal, SH | 1 |
| Fahn, S | 1 |
| De Cuypere, G; Jannes, C; Remouchamps, A; Tack, E | 1 |
| Klawans, HL | 1 |
| Breck, L; Cedarbaum, JM; Kutt, H; McDowell, FH | 1 |
1 review(s) available for levodopa and Paranoia
| Article | Year |
|---|---|
Psychiatric side effects during the treatment of Parkinson's disease.
Topics: Dreams; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Mental Disorders; Paranoid Disorders; Parkinson Disease; Serotonin; Severity of Illness Index; Sleep Wake Disorders | 1988 |
10 other study(ies) available for levodopa and Paranoia
| Article | Year |
|---|---|
Integrated theory to unify status among schizophrenia and manic depressive illness.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Biopterins; Bipolar Disorder; Blood-Brain Barrier; Depression; Depression, Postpartum; Dopamine; Female; Hallucinations; Humans; Kynurenic Acid; Levodopa; Male; Neuroleptic Malignant Syndrome; Neurotransmitter Agents; Paranoid Disorders; Premenstrual Syndrome; Schizophrenia; Seasonal Affective Disorder; Serotonin; Serotonin Syndrome; Tyrosine | 2015 |
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychotic Disorders | 1993 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
[Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Delusions; Female; France; Hallucinations; Health Surveys; Humans; Inpatients; Levodopa; Male; Middle Aged; Outpatients; Paranoid Disorders; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders | 2002 |
Nonconfusional paranoid psychosis secondary to anticholinergics?
Topics: Hallucinations; Humans; Levodopa; Paranoid Disorders; Parasympatholytics | 1978 |
Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects.
Topics: Amphetamine; Dextroamphetamine; Dopamine; Humans; Levodopa; Male; Paranoid Disorders; Piribedil; Psychoses, Substance-Induced; Schizophrenia | 1977 |
Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
A therapeutic approach to tardive dyskinesia.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Colitis; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Nausea; Paranoid Disorders; Psychomotor Agitation; Psychoses, Substance-Induced; Psychotic Disorders; Receptors, Dopamine; Reserpine; Tetrabenazine; Time Factors | 1985 |
Levodopa addiction. A case study.
Topics: Adult; Dermatitis, Seborrheic; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Muscle Rigidity; Paranoid Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Risk Factors; Substance Withdrawal Syndrome; Substance-Related Disorders | 1988 |
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Paranoid Disorders; Parkinson Disease; Patient Acceptance of Health Care; Time Factors | 1987 |